Dexpramipexole| CAS 104632-28-2

Cas No.:	104632-28-2
Chemical Name:	(R)-Pramipexole 2HCl
Synonyms:	(R)-Pramipexole;(R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine;R-(+)-Pramipexole;(R)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazolediamine Dihydrochloride;(R)-Pramipexole Dihydrochloride;R-(+)-Pramipexole Dihydrochloride;Pramipexole Related Compound D (25 mg) ((R)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole);DexpraMipexole;(6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;(R)-Pramipexole Dihy;(S)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine;2,6-Benzothiazolediamine, 4,5, 6,7-tetrahydro-N6-propyl-, (6R)-;(6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole;(6R)-4,5,6,7-tetrahydro-N6-propylbenzothiazole-2,6-diamine;(R)-(+)-2-amino-4,5,6,7-tetrahydro-6-(n-propylamino)benzothiazole;(R)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine;KNS-760704;Pramipexole [USAN:INN];PraMipexole Related CoMpound D;(6R)-N6-propyl-3a,4,5,6,7,7a-hexahydrobenzo[d]thiazole-2,6-diamine;FASDKYOPVNHBLU-SSDOTTSWSA-N;2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6R)-;MLS006011813;AS-56557;DEXPRAMIPEXOLE [USAN];(6R)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;104632-28-2;CS-1196;Q5268345;DB15130;Dexpramipexole [USAN:INN];EN300-123062;NS00008478;DEXPRAMIPEXOLE [WHO-DD];2,6-BENZOTHIAZOLEDIAMINE, 4,5,6,7-TETRAHYDRO-N6-PROPYL-, (R)-;BDBM50568780;UNII-WI638GUS96;(R)-Pramipexole;R-(+)-Pramipexole;KNS-760704;DTXSID50146624;AC-36724;HY-17355B;Dexpramipexole (USAN/INN);(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine;F19514;(R)-4,5,6,7-TETRAHYDRO-6-(PROPYLAMINO)-BENZOTHIAZOLE-2-AMINE;AKOS005555111;D09886;SMR004703492;CHEMBL249420;DEXPRAMIPEXOLE [INN];WI638GUS96;SCHEMBL74780;BCP12512;2-Amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazole; 4,5,6,7-Tetrahydro-N6-propyl-2,6-Benzothiazolediamine;;Dexpramipexole;DA-62809;(6R)-N~6~-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine;STK621530;(R)-PRAMIPEXOLE;DEXPRAMIPEXOLE DIHYDROCHLORIDE;(R)-N6-Propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine;2,6-BenzothiazolediaMine, 4,5, 6,7-tetrahydro-N6-propyl-, (6R)-
SMILES:	NC1=NC(CC[C@@H](NCCC)C2)=C2S1
Formula:	C₁₀H₁₇N₃S
M.Wt:	211.32708
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively; also possesses low/insignificant affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors; used for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Alzheimer's DiseasePhase 2 Clinical

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.